Core Enterprise Operations & Scientific Focus

Bristol Myers Squibb operates an end-to-end biopharmaceutical model encompassing early-stage drug discovery, clinical development, regulatory approval navigation, large-scale commercial manufacturing, and worldwide distribution.

1. Research & Early Discovery

The company’s R&D enterprise combines internal innovation hubs—located in major biotechnology clusters such as Cambridge, Massachusetts, San Diego, California, and Princeton, New Jersey—with strategic external collaborations. Core research platforms center on: * Immuno-Oncology: Harnessing the body’s immune system to identify and destroy tumor cells. * Targeted Protein Degradation (TPD): Utilizing molecular glues and heterobifunctional degradation agents (CELMoDs) to degrade disease-causing proteins. * Cell Therapy: Designing personalized living drugs using engineered T-cells (CAR-T therapy). * Genomic and Precision Medicine: Utilizing genetic profiling to target specific patient subpopulations for optimized therapeutic outcomes.

2. Manufacturing and Supply Chain Management

BMS maintains global manufacturing and supply chain networks capable of producing complex biological therapies, small-molecule synthetic pharmaceuticals, and living cell therapies. Cell therapy manufacturing facilities require specialized autologous patient-to-dose logistics, where patient T-cells are harvested, re-engineered in sterile environments, and re-infused into the patient under strict regulatory guidelines.

3. Commercial Operations and Global Access

BMS markets its product portfolio globally through relationships with healthcare providers, hospital networks, health maintenance organizations, government entities, and distributors. The organization engages in value-based healthcare programs and access initiatives to deliver treatments to markets around the world.

Major Commercial Products and Therapeutic Portfolios

Bristol Myers Squibb’s product catalog includes market-leading therapeutics across several distinct therapeutic divisions:

1. Oncology (Solid Tumors)

BMS is a pioneer in immuno-oncology, introducing checkpoint inhibitors that block specific proteins (such as PD-1 and CTLA-4) to restore T-cell recognition of cancer cells.

• Opdivo (nivolumab): A human monoclonal antibody that blocks the PD-1 receptor. It is approved globally for numerous cancer types, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, classical Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, esophageal cancer, and gastric cancer.
• Yervoy (ipilimumab): A CTLA-4 immune checkpoint inhibitor that works synergistically with Opdivo or as monotherapy in advanced melanoma, renal cell carcinoma, non-small cell lung cancer, and colorectal cancer.
• Opdualag (nivolumab and relatlimab-rmbw): A fixed-dose combination of the PD-1 inhibitor nivolumab and the LAG-3 blocking antibody relatlimab, approved for unresectable or metastatic melanoma.
• Krazati (adagrasib): A targeted inhibitor of the KRAS G12C mutation used for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer and colorectal cancer.

2. Hematology (Blood Cancers)

Through internal research and the landmark acquisition of Celgene Corporation, BMS possesses a dominant portfolio in hematologic malignancies, including multiple myeloma, myelodysplastic syndromes, and lymphomas.

• Revlimid (lenalidomide): An immunomodulatory agent widely used in combination regimens for the treatment of multiple myeloma and myelodysplastic syndromes (MDS).
• Pomalyst / Imnovid (pomalidomide): An immunomodulatory agent indicated for patients with relapsed or refractory multiple myeloma who have received prior therapies.
• Sprycel (dasatinib): A targeted kinase inhibitor used in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).
• Inrebic (fedratinib): An oral kinase inhibitor approved for intermediate-2 or high-risk primary or secondary myelofibrosis.
• Reblozyl (luspatercept-aamt): An erythroid maturation agent developed in collaboration with Merck (formerly Acceleron Pharma) for the treatment of anemia in adult patients with beta-thalassemia and myelodysplastic syndromes.
• Breyanzi (lisocabtagene maraleucel): A CD19-directed autologous CAR T-cell therapy approved for relapsed or refractory large B-cell lymphoma and follicular lymphoma.
• Abecma (idecabtagene vicleucel): A BCMA-directed autologous CAR T-cell therapy indicated for adult patients with relapsed or refractory multiple myeloma.

3. Cardiovascular

BMS produces leading therapies targeting cardiovascular and thromboembolic conditions.

• Eliquis (apixaban): Developed and commercialized in collaboration with Pfizer, Eliquis is an oral direct Factor Xa inhibitor anticoagulant. It is prescribed to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).
• Camzyos (mavacamten): A first-in-class cardiac myosin inhibitor indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.

4. Immunology and Inflammation

BMS provides biologic and targeted synthetic therapies for severe autoimmune and inflammatory conditions.

• Orencia (abatacept): A selective T-cell costimulation modulator used to treat moderate to severe rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis, as well as for prophylaxis against acute graft-versus-host disease (aGVHD).
• Zeposia (ozanimod): A sphingosine 1-phosphate (S1P) receptor modulator approved for the treatment of relapsing forms of multiple sclerosis (RMS) and moderately to severely active ulcerative colitis.
• Sotyktu (deucravacitinib): An oral, selective allosteric TYK2 inhibitor approved for the treatment of adults with moderate-to-severe plaque psoriasis.

5. Neuroscience

• Cobenfy (xanomeline and trospium chloride): A dual M1/M4 preferring muscarinic receptor agonist and muscarinic receptor antagonist formulation indicated for the treatment of schizophrenia in adults, representing a novel non-dopaminergic mechanism of action in psychiatric care.

Services & Patient Support Programs

In addition to developing and manufacturing pharmaceutical therapies, Bristol Myers Squibb provides comprehensive specialized services and resources to support patient care delivery and clinical advancement:

• BMS Access Support: Program delivering coverage assistance, co-pay help, reimbursement support, and free medication programs for eligible uninsured or underinsured patients prescribed BMS products.
• Clinical Trial Portals and Research Support: Dedicated services facilitating clinical trial discovery, investigator-initiated research grants, and data-sharing platforms for scientific researchers.
• Diagnostic & Biomarker Testing Initiatives: Partnering with medical labs globally to expand access to precision biomarker testing (such as PD-L1 expression testing and KRAS mutation identification) so patients can be matched with appropriate targeted therapies.
• Educational Platforms: Providing accredited medical education programs, disease-state awareness campaigns, and patient community support resources across oncology, hematology, and autoimmune diseases.